Vascular cardiologist: AUGUSTUS trial clearly identifies that apixaban is preferable to warfarin in patients with AFib and recent PCI or ACS who require both #cvCoag and antiplatelet drugs #ACC19


Expert Pitch

Geoffrey Barnes, M.D., vascular cardiologist at Michigan Medicine (University of Michigan)'s Frankel Cardiovascular Center, comments on importance of late-breaking clinical trial AUGUSTUS at the American College of Cardiology Scientific Sessions.

"The AUGUSTUS trial clearly identifies that apixaban is preferable to warfarin in patients with AFib and recent percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS) who require both anticoagulation and antiplatelet drugs.

The trial confirms the safety of stopping aspirin therapy in patients on concurrent anticoagulants and P2Y12 antiplatelet therapy following PCI or ACS."

Barnes' credentials/bio: https://www.umcvc.org/profile/3549/geoffrey-douglas-barnes-md

  • share-facebook-Vascular cardiologist: AUGUSTUS trial clearly identifies that apixaban is preferable to warfarin in patients with AFib and recent PCI or ACS who require both #cvCoag and antiplatelet drugs #ACC19
  • share-twitter-Vascular cardiologist: AUGUSTUS trial clearly identifies that apixaban is preferable to warfarin in patients with AFib and recent PCI or ACS who require both #cvCoag and antiplatelet drugs #ACC19

Comment/Share

Chat now!